Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.37 +0.19 (+0.38%)

Official Closing Price Updated: 4:10 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Novo Nordisk Stock Is Plummeting. Time to Panic, or Is This an Opportunity? ↗

July 30, 2025

NVO stock is now down 65% from last year's high.

Via The Motley Fool

Rosen Law Firm Encourages Novo Nordisk A/S Investors to Inquire About Securities Class Action Investigation – NVO

July 30, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS' ↗

July 30, 2025

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity drug Wegovy.

Via Benzinga

Unitedhealth, Starbucks, Novo Nordisk, UPS And Meta: Why These 5 Stocks Are On Investors' Radars Today ↗

July 29, 2025

UNH, SBUX, NVO, UPS, META were among the stocks seen trending on Tuesday, July 29, 2025.

Via Benzinga

Novo Nordisk, SoFi Tech, PayPal, UnitedHealth, Spotify: Stocks Making The Biggest Moves Today ↗

July 29, 2025

Via Stocktwits

Why Eli Lilly Stock Was Looking Sickly Today ↗

July 29, 2025

It seemed the market overreacted to discouraging news from one of the company's rivals.

Via The Motley Fool

History of Novo Nordisk A/S Stock: From Insulin Pioneers to Global Pharma Leader (NYSE:NVO)

July 29, 2025

Novo Nordisk A/S (NYSE:NVO) has evolved over the past century from a humble insulin manufacturer in Denmark into one of the world’s most valuable pharmaceutical companies. With a commanding presence in...

Via MarketMinute

Topics Economy Emissions

Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)

July 29, 2025

In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at...

Via MarketMinute

Topics ETFs Economy

Why NovoCure Stock Is Cratering Today ↗

July 29, 2025

The Ozempic maker's stock is dropping fast -- here's why.

Via The Motley Fool

Topics Stocks

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock ↗

July 29, 2025

Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after...

Via Stocktwits

What's Going On With Eli Lilly Stock On Tuesday? ↗

July 29, 2025

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.

Via Benzinga

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views ↗

July 29, 2025

Via Benzinga

Topics Earnings

Novo Nordisk Stock Slumps After Slashing Full-Year Guidance, But Retail Has Its Eyes On An Oral Weight Loss Drug ↗

July 29, 2025

The company now expects full-year sales growth of 8% to 14% at a constant exchange rate, down from its previous estimate of 13% to 21%.

Via Stocktwits

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

July 29, 2025

From The Schall Law Firm

Via Business Wire

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting? ↗

July 29, 2025

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Via Benzinga

Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. ↗

July 29, 2025

Novo Nordisk lowered its full-year guidance and named a new CEO. The pharma giant's shares plunged in early trades.

Via Investor's Business Daily

Topics Artificial Intelligence

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO ↗

July 29, 2025

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

July 29, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

3 Surprisingly Underrated Stocks to Buy Right Now ↗

July 28, 2025

These big pharma stocks arguably aren't receiving the respect they deserve.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks That Are Losing to the S&P 500 This Year ↗

July 27, 2025

Wall Street might be underestimating these companies' potential.

Via The Motley Fool

Topics Stocks

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China ↗

July 25, 2025

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market.

Via Benzinga

Topics Law Enforcement Supply Chain

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case ↗

July 25, 2025

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims.

Via Benzinga

Topics Intellectual Property

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Meets Caviar Cruise Standards for Quality Investing ↗

July 25, 2025

The Caviar Cruise stock screener identifies top long-term investments like Novo Nordisk (NVO), with strong revenue growth, high ROIC, solid cash flow, and pricing power—ideal for quality investors.

Via Chartmill

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years ↗

July 24, 2025

Via Benzinga

Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs ↗

July 23, 2025

Via Benzinga

2 Beaten-Down Dividend Growth Stocks to Buy on the Dip ↗

July 22, 2025

Via The Motley Fool

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade ↗

July 21, 2025

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.